Palvella Therapeutics, Inc. (PVLA) is making strides in the rare-disease dermatology sector with its proprietary QTORIN platform, which reformulates active molecules for topical treatments. The company's lead candidate, QTORIN rapamycin, has shown promising results in treating mLM, bolstered by positive data from recent studies. PVLA has also received favorable feedback from the FDA, which enhances its credibility and supports a targeted New Drug Application (NDA) submission for QTORIN rapamycin in the second half of 2026. In addition to mLM, the QTORIN platform has potential applications in other conditions such as cVM, angiokeratomas, and DSAP, which could provide further growth opportunities. Although the stock has experienced a recent uptrend, analysts suggest that a period of consolidation may be on the horizon. Nonetheless, the long-term outlook for Palvella Therapeutics remains optimistic as the company continues to develop its QTORIN platform.